Piperacillin/Tazobactam Kabi Powder For Solution For Infusion 4g/0.5g

Piperacillin/Tazobactam Kabi is an intravenous antibiotic combination developed by Fresenius Kabi, a German healthcare company. The product combines the extended-spectrum penicillin piperacillin with the beta-lactamase inhibitor tazobactam, enhancing its efficacy against a broad spectrum of Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. This combination is used to treat severe infections such as hospital-acquired pneumonia, complicated urinary tract infections, intra-abdominal infections, and skin and soft tissue infections. The manufacturing of this product occurs in multiple countries, reflecting Fresenius Kabi's global production capabilities. As of 2025, Fresenius Kabi continues to be the ultimate owner of the Piperacillin/Tazobactam Kabi brand, maintaining its headquarters in Germany. The company operates worldwide, providing critical care medicines and technologies to healthcare providers globally.